BIOMARKER:

KEAP1 mutation

B | Sensitive

C2 | Sensitive

C3 | Sensitive

D | Sensitive

B | Resistant

C2 | Resistant

C3 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Lung Adenocarcinoma

Lung Non-Squamous Non-Small Cell Cancer

Solid Tumor

Lung Non-Small Cell Squamous Cancer

Lung Cancer

camrelizumab + rivoceranib

KEAP1 mutation|Non Small Cell Lung Cancer|camrelizumab + rivoceranib

KEAP1 mutation|Lung Non-Squamous Non-Small Cell Cancer|camrelizumab + rivoceranib

IPN60090

KEAP1 mutation|Solid Tumor|IPN60090

KEAP1 mutation|Lung Cancer|IPN60090

DRP-104

KEAP1 mutation|Non Small Cell Lung Cancer|DRP-104

KEAP1 mutation|Lung Adenocarcinoma|DRP-104

durvalumab + tremelimumab

KEAP1 mutation|Non Small Cell Lung Cancer|durvalumab + tremelimumab

CB-228

KEAP1 mutation|Lung Non-Small Cell Squamous Cancer|CB-228

CB-228 + CB-839

KEAP1 mutation|Lung Adenocarcinoma|CB-228 + CB-839

pembrolizumab + ramucirumab

KEAP1 mutation|Non Small Cell Lung Cancer|pembrolizumab + ramucirumab

docetaxel

KEAP1 mutation|Lung Non-Squamous Non-Small Cell Cancer|docetaxel

atezolizumab

KEAP1 mutation|Non Small Cell Lung Cancer|atezolizumab

KEAP1 mutation|Lung Non-Squamous Non-Small Cell Cancer|atezolizumab

durvalumab

KEAP1 mutation|Non Small Cell Lung Cancer|durvalumab

Immunotherapy

KEAP1 mutation|Non Small Cell Lung Cancer|Immunotherapy

KEAP1 mutation|Lung Adenocarcinoma|Immunotherapy

PD-L1 inhibitor

KEAP1 mutation|Non Small Cell Lung Cancer|PD-L1 inhibitor